Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aricept Clear all
Completed Phase 1Phase 2 Interventional Results available

The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism

NCT00695136
View directory record Official record
Conditions
Autism, Cognition Disorder
Interventions
Donepezil hydrochloride, Increase REM sleep percentage
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
2 Years to 10 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

NCT00293176
View directory record Official record
Conditions
Memory Loss
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
54
States / cities
Albaster, Alabama • Mesa, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment for Early Memory Loss

NCT00042172
View directory record Official record
Conditions
Cognition Disorders, Alzheimer Disease
Interventions
Donepezil, Ginkgo Biloba Extract
Drug
Lead sponsor
University of Iowa
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 2, 2014 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Aricept, Exelon, Nicoderm Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil TDS, Aricept
Combination Product · Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

NCT03030105
View directory record Official record
Conditions
Alzheimer Disease
Interventions
BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Phase 3 Interventional

Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome

NCT00069550
View directory record Official record
Conditions
Rett Syndrome
Interventions
dextromethorphan, donepezil hydrochloride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Year to 15 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Donepezil on Sedation and Other Symptoms

NCT00352664
View directory record Official record
Conditions
Advanced Cancer
Interventions
Donepezil, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil

NCT01845636
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Donepezil, Atropine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT03397862
View directory record Official record
Conditions
Skin Irritation, Sensitization
Interventions
Donepezil TDS, Vehicle TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

NCT00571064
View directory record Official record
Conditions
Mild to Severe Alzheimer's Disease
Interventions
Donepezil HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
Device · Drug
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Brunswick, New Jersey • North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

NCT02968719
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

NCT00408525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donepezil
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02406261
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Simvastatin, Midazolam, Donepezil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 1, 2026, 8:23 PM EDT